 Erhan Ararat
Concepts (115)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 2 | 2025 | 82 | 1.610 |
Why?
| | Asthma | 3 | 2025 | 313 | 1.480 |
Why?
| | Adrenal Cortex Hormones | 2 | 2025 | 116 | 1.070 |
Why?
| | Breast Neoplasms | 11 | 2015 | 1203 | 1.040 |
Why?
| | Organoids | 2 | 2022 | 35 | 0.910 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 223 | 0.810 |
Why?
| | Anti-Asthmatic Agents | 1 | 2023 | 33 | 0.810 |
Why?
| | Lung | 3 | 2022 | 479 | 0.700 |
Why?
| | Aspirin | 2 | 2011 | 122 | 0.620 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2025 | 570 | 0.600 |
Why?
| | Cystic Fibrosis | 1 | 2021 | 160 | 0.590 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 318 | 0.540 |
Why?
| | Neoadjuvant Therapy | 3 | 2013 | 124 | 0.420 |
Why?
| | Adolescent | 6 | 2025 | 6713 | 0.410 |
Why?
| | Child | 5 | 2025 | 7194 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 1020 | 0.340 |
Why?
| | Imidazoles | 1 | 2010 | 114 | 0.320 |
Why?
| | Diphosphonates | 1 | 2010 | 92 | 0.310 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 235 | 0.310 |
Why?
| | Protein Phosphatase 1 | 1 | 2009 | 6 | 0.310 |
Why?
| | Losartan | 1 | 2009 | 27 | 0.300 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 47 | 0.300 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 48 | 0.300 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 123 | 0.300 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 44 | 0.300 |
Why?
| | Isoenzymes | 1 | 2009 | 171 | 0.290 |
Why?
| | MAP Kinase Signaling System | 1 | 2009 | 128 | 0.290 |
Why?
| | Humans | 21 | 2025 | 52441 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 525 | 0.280 |
Why?
| | Female | 16 | 2025 | 28277 | 0.250 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 1216 | 0.230 |
Why?
| | Propensity Score | 1 | 2025 | 160 | 0.220 |
Why?
| | Allergy and Immunology | 1 | 2024 | 19 | 0.220 |
Why?
| | Preoperative Care | 1 | 2024 | 173 | 0.190 |
Why?
| | Blood Glucose | 1 | 2025 | 483 | 0.190 |
Why?
| | Home Care Services | 1 | 2023 | 70 | 0.190 |
Why?
| | Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.190 |
Why?
| | Medicaid | 1 | 2024 | 264 | 0.180 |
Why?
| | Young Adult | 4 | 2023 | 4346 | 0.170 |
Why?
| | Body Height | 1 | 2021 | 65 | 0.170 |
Why?
| | Mass Screening | 1 | 2024 | 354 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2023 | 288 | 0.170 |
Why?
| | Disease Progression | 1 | 2023 | 870 | 0.170 |
Why?
| | Anthracyclines | 2 | 2011 | 34 | 0.170 |
Why?
| | Nutritional Status | 1 | 2021 | 146 | 0.160 |
Why?
| | Male | 6 | 2025 | 26874 | 0.150 |
Why?
| | Incidence | 2 | 2011 | 1096 | 0.140 |
Why?
| | Child, Preschool | 2 | 2024 | 4046 | 0.130 |
Why?
| | Retrospective Studies | 4 | 2024 | 6694 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2010 | 3013 | 0.120 |
Why?
| | Adult | 5 | 2023 | 14205 | 0.120 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2015 | 30 | 0.110 |
Why?
| | Receptors, Progesterone | 2 | 2013 | 68 | 0.110 |
Why?
| | Cardiomyopathies | 1 | 2015 | 117 | 0.110 |
Why?
| | Receptor, erbB-2 | 2 | 2013 | 79 | 0.110 |
Why?
| | Receptors, Estrogen | 2 | 2013 | 133 | 0.100 |
Why?
| | Axilla | 1 | 2013 | 92 | 0.100 |
Why?
| | Prognosis | 3 | 2015 | 2100 | 0.100 |
Why?
| | Heart | 1 | 2015 | 352 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2013 | 210 | 0.090 |
Why?
| | Phenotype | 1 | 2015 | 792 | 0.090 |
Why?
| | Survival Rate | 2 | 2013 | 944 | 0.090 |
Why?
| | Dacarbazine | 1 | 2011 | 10 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2013 | 253 | 0.090 |
Why?
| | Opportunistic Infections | 1 | 2011 | 56 | 0.090 |
Why?
| | Deoxycytidine | 1 | 2011 | 24 | 0.090 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 78 | 0.090 |
Why?
| | Fluorouracil | 1 | 2011 | 56 | 0.090 |
Why?
| | Genes, BRCA1 | 1 | 2011 | 18 | 0.090 |
Why?
| | Phthalazines | 1 | 2011 | 20 | 0.090 |
Why?
| | Drugs, Generic | 1 | 2010 | 7 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 639 | 0.080 |
Why?
| | Taxoids | 1 | 2010 | 38 | 0.080 |
Why?
| | Tamoxifen | 1 | 2010 | 60 | 0.080 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 56 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 125 | 0.080 |
Why?
| | Captopril | 1 | 2009 | 13 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 94 | 0.070 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 73 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2015 | 122 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 269 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 135 | 0.070 |
Why?
| | Aorta | 1 | 2009 | 170 | 0.070 |
Why?
| | Ventricular Function, Left | 1 | 2009 | 174 | 0.070 |
Why?
| | Age Factors | 1 | 2011 | 1120 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2011 | 2294 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 1558 | 0.060 |
Why?
| | Apoptosis | 1 | 2010 | 1120 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2009 | 449 | 0.060 |
Why?
| | Mutation | 1 | 2011 | 1331 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2013 | 5508 | 0.050 |
Why?
| | Respiration | 1 | 2023 | 99 | 0.050 |
Why?
| | Heart Failure | 1 | 2009 | 527 | 0.050 |
Why?
| | Rats | 1 | 2009 | 3228 | 0.050 |
Why?
| | Tracheostomy | 1 | 2023 | 76 | 0.050 |
Why?
| | Animals | 2 | 2022 | 13485 | 0.040 |
Why?
| | Stem Cells | 1 | 2022 | 186 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2022 | 217 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 521 | 0.040 |
Why?
| | Hospitalization | 1 | 2024 | 731 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2022 | 667 | 0.040 |
Why?
| | Arkansas | 1 | 2024 | 2013 | 0.040 |
Why?
| | Infant | 1 | 2024 | 3709 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2015 | 90 | 0.030 |
Why?
| | Aged | 3 | 2013 | 10242 | 0.030 |
Why?
| | United States | 1 | 2024 | 5215 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2013 | 278 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 461 | 0.020 |
Why?
| | Mice | 1 | 2022 | 5899 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2010 | 35 | 0.020 |
Why?
| | Arthralgia | 1 | 2010 | 44 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 370 | 0.020 |
Why?
| | Middle Aged | 2 | 2013 | 13133 | 0.020 |
Why?
| | Risk Factors | 1 | 2015 | 3971 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2013 | 3449 | 0.010 |
Why?
|
|
Ararat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|